NCT03335839CompletedPhase 3
Adjunctive, Low-dose tPA in Primary PCI for STEMI
Adjunctive, Low-dose Intracoronary Recombinant Tissue Plasminogen Activator (tPA) Versus Placebo for Primary PCI in Patients With ST-segment Elevation Myocardial Infarction
Source: ClinicalTrials.gov · Last updated 18 Jun 2026
Brief summary (registry, in English)
STRIVE will evaluate the use of adjunctive, low-dose intracoronary tissue plasminogen activator during primary percutaneous coronary intervention (PCI) for patients with ST elevation myocardial infarction (STEMI) in reducing the incidence of post-procedural myocardial blush (MBG) grade 0/1 or distal embolization.
- Status (registry)
- Completed
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 210 (actual)
- First submitted
- 3 Nov 2017
- Start date
- 1 Apr 2018
- Primary completion date
- 17 Sept 2024
- Lead sponsor
- Population Health Research Institute
- Diseases
- Coronary artery disease
- NCT number
- NCT03335839
What you commit to
- Study type: Interventional · Phase 3
- Participants enrolled: 210
- From 1 Apr 2018 to the primary completion date, 17 Sept 2024
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Active internal bleeding or high risk of bleeding or any prior intracranial bleeding.
- Any other absolute or relative contraindication to fibrinolytic therapy.
- Administration of a fibrinolytic ≤24hrs prior to randomization.
- Planned upfront use of a glycoprotein IIb/IIIa inhibitor.
Other
- Cardiogenic shock on presentation.
- Left bundle branch block (excluded because the ECG cannot be evaluated for ST segment resolution, an outcome of the study).
- Any medical, geographic, or social factor making study participation impractical or precluding 1 month follow-up.
Who the study is looking for
- Patients with STEMI undergoing primary PCI and,
- ECG changes indicating large territory STEMI (defined as ≥2mm ST-segment elevation in 2 contiguous anterior precordial leads; or ≥2mm ST-segment elevation in 2 inferior leads coupled with ST-segment depression in 2 contiguous anterior leads for a total ST-segment deviation of ≥8mm) and,
- Randomization within 6 to 12 hours of symptom onset and,
- Large thrombus burden with angiographic TIMI Thrombus Grade ≥3 after guidewire crossing.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Calgary- Foothills Medical Centre Coordinator of this site? Confirm its status | Calgary | Canada | Unknown status |
| University of Alberta - Mazankowski Alberta Heart Insitute Coordinator of this site? Confirm its status | Edmonton | Canada | Unknown status |
| Hamilton General Hospital Coordinator of this site? Confirm its status | Hamilton | Canada | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.